PTO/SB/08B (08-03) Approved for use through 07/31/2006, OMB 0651-0031 rademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO			Complete if Known			
000000000000000000000000000000000000000	J. 10		Application Number	09/700,101		
INFORMAT	ION DIS	CLOSURE	Filing Date	11/8/2000	· · · · · · · · · · · · · · · · · · ·	
STATEMEN	STATEMENT BY APPLICANT			Glick, et al		
(lles se m			Art Unit	1618		
(Use as many sheets as necessary)			Examiner Name	Kim, Vickie Y		
Sheet 1	of	1	Attorney Docket Number	UM-07268		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
1	1	Snyder, Jane R., Chemistry & Biol., 12, (2005), 477-484	
	12	Williams, Darren, Chemistry & Biol., 11, (2004), 1251-1259	
	_		
Examiner		Date	P
Signature		Considered 3/30/56	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Sheet 1

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Output

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Output

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	09/700, 101				
Filing Date	11/08/2000				
First Named Inventor	GLICK, et al				
Art Unit	1618				
Examiner Name	Kim, Vickie Y				
Attorney Docket Number	UM-07268				

			U. S. PATENT	DOCUMENTS		
Examiner Cite No.		Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
1	1	^{US-} 6,767,533	07/27/2004	Casellas	Whole Document	
7	2	^{US-} 6,506,744	01/14/2003	Alig	Whole Document	
0		US-				
		US-				
		US-				
		US-				
		US-				
· · · · · · · ·		US-				
······································		US-				
_		us-				
		US-				
		US-	ĺ			
		US-				
		US-	<u> </u>			
		US-				
		US-				
		US-				
·		US-	···			
		us-				

	FORE	GN PATENT DOCU	MENTS		
Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages	
	Country Code ³ Number ⁴ Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		L			
				,	
		í			
		No.1 Foreign Patent Document	Cite Foreign Patent Document Publication Date MM-DD-YYYY	No. Date Applicant of Cited Document	Cite Foreign Patent Document Publication Name of Patentee or No.1 Publication Name of Patentee or Applicant of Cited Document MM-DD-YYYY Mere Relevant Fourse Appear

Examiner	λ	Date	213	1 -
Signature		Considered	7 10	1%

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Un	the Paperwork Red te for form 1449/PTO	luction A	ct of 1995, no persons ar	e required to respond to a collection	of information unless it contains a valid OMB control Complete if Known	d number.
	(810110m) 1448/P1O			Application Number	09/700,101	
INF	ORMATION	I DIS	CLOSURE	Filing Date	11/08/2000	•
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	Glick	
	(lies as mony she	nafe se s	accessori	Art Unit	1618	
(Use as many sheets as necessary)				Examiner Name	Kim, Vickie Y.	
Sheet	2	of	2	Attorney Docket Number	UM-07268	

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
Y	3	Parks, Daniel J. Bioorg Med Chem. Ltrs,. 15,(2005), 765-770	
	4	Raboisson, P. Bioorg Med Chem. Ltrs., 15,(2005), 1857-1861	
	5	Hulme, C. J. Org. Chem., 63,(1998), 8021-8023	
	6	Kamal, A. Synlett, 14,(2004), 2533-35	
4	7	Grasberger, Bruce L., J. Med. Chem., 48, (2005), 909-912	
	,		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

SEP 0 6 2005

PTO/SB/08B (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO		EMARIA SONO DEFISIONS AS	e required to respond to a conection	of information unless it contains a valid OMB control Complete if Known	number.
Substitution (Amilian)				Application Number	09/700,101	-
INF	ORMATION	DIS	CLOSURE	Filing Date	11/08/2000	
STA	STATEMENT BY APPLICANT			First Named Inventor	Gary D. Glick et al.	
	##			Art Unit	Not Assigned	-
(Use as many sheets as necessary)			ecessary)	Examiner Name	Not Assigned	
Sheet	1	of	1	Attorney Docket Number	UM-07268	7

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
V	Beurdeley-Thomas et al., Journal of Neuro-Oncology 46 (2000) 45-56				
	2	Churcher et al., Bioorganic & Medicinal Chemistry Letters 13 (2003) 179-183			
	3	Darrow et al., Bioorganic & Medicinal Chemistry Letters 8 (1998) 3127-3132			
	4	Herranz, Medicinal Research Reviews 23 (2003) 559-603			
	5	Ramdas et al., Archieves of Biochemistry and Biophysics 368 (1999) 394-400			
V	6	Ursini et al., J. Med. Chem. 43 (2000) 3596-3613			

Examiner Signature Date Considered 3 30 3 5

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Onsidered. Include copy of this form with next communication to applicants.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

FORM PTO-14	149	U.S. Departme	ent of Commerce	4.05	Attorney Docket No.: UN	1-07268	Serial No.: 09/	700,101	
(Modified)		_	Patent and Tradema	irk Office					
INF	ORMATI	op niscrostar s	TATEMENT BY API	PLICANT					
	,	(Use Several Sheet							
	/		8						
(37 CFR ? 1.9)8(ъ))	APR 0 6 2305	빙				<u> </u>		
	/		<u>\$</u> /		Applicant: Gary D. Glick	et al.	1		
		MADE			Filing Date: 11/08/2000	<u> </u>	Group Art Unit	<u> </u>	
		THAUC		U.S. PATENT DOC		,	ı i	·	
Examiner	Cite	Senal / Patent	Issue Date	Applic	ant / Patentee	Class	Subclass	Filing	, Date
Initials	No.	Number	05/05/1000						
W	1	5,776,946	07/07/1998	Mo	Geer et al.	514	307	08/28	/1993
	2	5,288,514	2/22/940	<u> </u>	Ellman	427	29.6	9/14	/92
		r	FOREIGN PATENTS	OR PUBLISHED FOR	REIGN PATENT APPLICAT	TIONS	 		
		Document	Publication Date	Country	/ Patent Office	Class	Subclass	Trans	lation
		Number					1		
17								Yes	No
V -	3	WO 99/29347	17 June 1999		<u>wo</u>		 		
	4	WO 99/58117	18 Nov 1999		WO				ļ
- //-	. 5	DE 1810423	11.5 1006	·	ermany				
-	6	EP 0 227 539 B1	11 Dec 1986	<u> </u>	EPO				
 	 		 						
					· · · · · · · · · · · · · · · · · · ·				
	L	OTUE	D DOCLIMENTS (Inc	Juding Author Title D	ate, Relevant Pages, Place of	f Dublication)	<u> </u>		<u> </u>
1	7	ı	Chem. 38:3502-3507		ate. Relevant Pages, Place U	[Fuorication]			
7	8		Chem. Soc. 9:375-379 (
Y/	9				Prenatal Benzodiazepines,"	Toxic. In Vitro - 8	3(5):1061-1065(19	94).	
			· · · · · · · · · · · · · · · · · · ·						
						1			
Examiner:		n			Date Considered:	3/3	006		
EXAMINER:	Init	tial citation considered.	Draw line through cit	ation if not in conform	ance and not considered. Inc	clude copy of this	form with next or	mmunicati	on to
applicant.									

		OIP	E				PTO/SB/08 (2/92 Sheet 1 of 1
Form PT	0-144	9 MAR 2	5 2002	Docket No. UM 2038.01 Appl. No. 09/700,101—4		/700.101 4	
INFORMATION DISCLOSURE STATEMENT				Applicant(s)	Applicant(s) Gary D. GLICK, et al.		APR 0 1
		everal sheets if n		Filing Date: November 8, 2	2000	Group Art Un	it: 1614 📆 🔟
	(036 36	verai sireets ii ii		PATENT DOCUMEN	ITS		2002 1600/2900
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)
	1.	08/21/01	6,277,844 B1	Spector et al.			
3	2.	11/20/01	6,319,931 B1	Kroemer et al.			
			0,010,001 11				
				SN PATENT DOCUM			
Examiner Initials	Ref. No.	Date	Document No.	Name	Clas s	Subclass	Translation YES NO
Examiner	Ref.	Title	0	THER DOCUMENTS		ng author, title,	date, perlinent pages, etc.)
Initials	No.						
				•			
							······································
			<u> </u>				
						·	
· · · · · · · · · · · · · · · · · · ·							
EXAMINE				DATE CON		30 / 36	
EXAMINER: considered. I	initial if c nclude a	copy of this form	d, whether or not the cita with next communication	ition conforms with MPEP 609. n to applicant.	Draw a line throug	in the citation if	not in conformance and no

Supplemental Form PTO-1449					Attorney's Docket No. 128019-203801 Application Serial No. 09/700,101						
					Applicant(s) Gary D. GLICK, et al.						
7 SUPPLY	KINIEM I Y	STATEME			Gary D. Octors, or an						
AY 2 1 3000	2 1 2021			Filing Date: November 8, 2000 Group Art Unit: 1614							
1	u Grasov	raral chaate	if necessary)		Filing Date: November 8, 2000	Gro	up Art Onit.	1014			
	Name and Address of			EU!S	RPATENT DOCUMENTS						
120000 Per	Ref.	Date	Document		Name	Class	Subclass	Filing Date			
Initials	No.		No.	4				(if appropr	iate)		
				-				 			
		<u> </u>	 	+				<u> </u>			
Zeri Z				ORE	GN PAVENTIDOGUMENUS 100 ASSECTI	NA TH	BAYER K		性調整		
Examiner	Ref.	Date	Document No.		Name .	Class	Subclass	Transla	tion		
Initials	No.	04/07/00	0.240.040.42	1.				YES	NO		
1	1.	01/07/89	0 349 949 A2	+	EPO	<u></u>					
			 	╅							
175 F "					ONHER DOCUMETINS						
			້ ທີ່ເອີຍປີດ		hor (itle, date, perdhent peres, ote); 💰						
Examiner	Ref.	Title									
Initials	No. 2.	Blum P., et	al "Stiff-Person Syn	drom	e: An Autoimmune Disease" Movement	isease" Movement Disorders, <u>6</u> (1): 12-20 (1991)					
	3.	Malgrange 7 (18): 304	B., et al., "Beta-Carb 1-3045 (1996)	oline	s Induce Apoptotic Death of Cerebellar G	iranule N	eurones in C	ulture" <i>Neun</i>			
	4.	Miller, K.A. Following	, et al., "Benzodiazep Transient Cerebral Iso	chemi	Prevent Neuronal Death By Apoptosis & ia" Society for Neuroscience Abstracts, 2	<u>24 (1-2):</u> :	979 (1998)				
	5.	1065 (1994)		omental Immunotoxicity of Prenatal Benz						
	6.	Mitochond	rial Transmembrane F	Poten	Receptor Agonists Modulate Thymocyte tial" <i>Jpn. J. Pharmacol.</i> , 79: 177-183 (19)	99)					
a	7.	Taupin V., the Produc 10 (1): 7-1	tion of Interleukin-1 a	Anxio and T	genic Peptide, ODN-Diazepam-Binding Ir umor Necrosis Factor by Human Monocy	ihibitor, a rtes" <i>Lyn</i>	and Benzodia aphokine and	zepines Enh Cytokine Re	ance esearch,		
<u> </u>		-									
	l										
	ļ	1									
	<u> </u>	-									
			· · · · · · · · · · · · · · · · · · ·								
<u> </u>	 -	 									
	 	 		-							

		
EXAMINER:	DATE CONSIDERED:	3170176
EXAMINER: Initial if citation considered, whether or not the not considered. Include a copy of this form with next comm		ine through the citation if not in conforma

PTO/SB/08 (2/92)

Form PT	0-14	40		Dooked No. 40004000	0004		Sheet 1 of 1		
·		73		Docket No. 128019203801 Appl. No. 09/700,1			o. 09/700,101		
OIPE	7		•	Applicant(s)					
/ INI	FORN	I NOITA	DISCLOSURE	Gary D. Glick					
MAR 1 9 2	204	STATE	MENT		Gary D. Glick				
3		1		Filing Date: Nov. 8, 20	00	Group A	rt Unit:		
100	COSe S	everal sheet	s if necessary)			Unassig	ned		
& TRADEM!			U.S. P	PATENT DOCUMENTS					
Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date (if appropriate)		
 		 							
	 				 				
		<u> </u>			<u> </u>				
	Ţ	.	FOREIGN	N PATENT DOCUMENT	S	·			
Examiner Initials	Ref.	Date	Document No.	Name	Class	Subclass	Translation		
initials	No.	 					YES NO		
		L		· · · · · · · · · · · · · · · · · · ·	<u>i </u>				
			ОТІ	HER DOCUMENTS					
Examiner	Ref.	Title			(includin	g author, title, o	date, pertinent pages, etc.)		
Initials	No.								
	1.	Partial In	ternational Search Repor	t for PCT/US00/41599					
<u> </u>						7			
				1	45	11 m			
						- PaC	They/		
						100			
 									
	 								
									
	-						·		
					Ţ		IJ		

MAR 2 1 2001 ECH CENTER 1600/2900

EXAMINER:	DATE CONSIDERED: うしゃ
EXAMINER: Initial if citation considered, whether or not the citation conforms considered. Include a copy of this form with next communication to applicant.	With MDED COO. D.

			JAN 1 6 2	ואי וססי					et 1 of 1
				Settorney's De	ocket No. 128019-203801	App	lication Seria	al No. 09/700),101
Sı	ıppiem	ental Form F	10-1-47	Applicant(s)					
INFORM	ATION	DISCLOSUF	RE STATEMENT DE		Gary D. C			Unacciona	
				,	November 8, 2000			Unassigned	I
(us	e seve	ral sheets if	necessary)	INSEPATENT DO	COMENIS ()				3. G. S. A.
			Document No.	Name	A 5.5.4.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5.5	Class	Subclass	Filing Date	
als N	lef. lo.	Date						(if appropr	iate)
				REIGNIPATENT	DOGUMENIJS:	HARRY			ALA: THE
	Ref.	Date	Document No.	Name		Class	Subclass	Transl:	NO
.,,,,,,,,	to.	Date				-			
	i	10/01/1990	0 349 949 A2	EPO	MEXTQ 2	A V et 2			
			(Includin	gauthor, title, dat	UMENIS : 3. Nootuoontoones (GD) :				
aminer	Ref.	Title					•		
tials	No.		al HOSSE Damon Sur	ndrome: An Autoi	mmune Disease," Moveme	ent Disor	ders – <u>6(1):12</u>	-20 (1991)	.Dorod
	2	Blum, P., et	aı., "Sım-Person Syr B., et al., "8-Carbolin	es Induce Apopto	mmune Disease," Movementic Death of Cerebellar Gra	anule Net	rones in Cul	tures," Neur	квроп
	3. 	<u>- 7</u> (18):3041	-3045 (1996)	A Maur	and Doath by Anontosis &	Necrosi	s in the Gerb	il Hippocamr	ous
	4.	Miller, K.A., Following T	et al., "Benzodiazep ransient Cerebral isc	chemia,""Society	for Neuroscience Abstract unotoxicity of Prenatal Be	s – <u>24(1-2</u> nzodiaze	:):979 (1998) pines," <i>Toxic</i>	c. In Vitro – 3	(5):1061-
1-1	5/	Schlumpf.	VI et al., "Delayed De	evelopmentai imm	unotoxicity of 1 fortates 25		•	Poduction (of the
+	6.	Tanimoto,	/., et al., "Benzodiaz	epine Receptor Ag	onists Modulate Thymocy Pharmacol. – 79:177-183	πε Apopt (1999)	osis i nrough	- Neudedon C	-banaa
1-/	7.	Mitochonde Taupin, V.,	et al., "Endogenous	Anxiogenic peptic	Pharmacol 19:171-163 de, ODN-Diazepam-Binding dis Factor by Human Mond	g Inhibito ocvtes." <i>L</i>	r, and Benzo ymphokine a	diazepines E and Cytokine	nhance <i>Researc</i>
W 1		the Produc - 10(1):7-1	tion of interleukin-1	and Tumor Necros					
		 							
		 							
		+							
	ļ								
	 	+							
	†								
	ļ								
		_	^			-D:	\ -	5 10/	
EXAMIN	ER:)	/\/		DATE CONSIDERE	:ט:	7	30 06	t in conf
		I if citation to	onsidered, whether or	r not the citation co	onforms with MPEP 609.)raw a line	anrougn(me	CIMPON II NO	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformation to applicant.									

154157.1 194749v1

PTO/SB/08 (2/92) Sheet 1 of 3

Form PTO-1449				Attorney's Docket No. 128019-203801 Application Serial No. 09/700,101						
INEC	DRAKTI	ON DIECLOS	IDE CTATEMENT	Applican	Applicant(s)					
INFC		UN DISCLUSE	JRE STATEMENT		Gary D. GLICK, et al.					
			£	Filing Da	te: November 8, 2000	Gro	up Art Unit:	Unassigned	d	
- 10 may 20 may		veral sheets i			DOCUMENTS					
Examiner	Ref.	Date	Document No.	Name	DOCOMENIO .	Class	Subclass	Filing Date		
Initials	No.					O.u.SS	Odbolass	(if appropr		
	1.	02/28/1978	4,076,823	Wade, et al						
	2.	08/29/1978	4,110,337	Szarvasi)			
	3.	01/22/1985	4,495,101	Klaubert, e	tal. OIA			12		
	4.	06/14/1988	4,751,223	Glamkowsi	ci, et al.	18	6/4,	C. T.		
	5.	08/20/1991	5,041,438	Hsu	JAN 0 C			7		
	6.	06/28/1994	5,324,726	Bock, et al.	MH 0 8 2001 2		WITCH 1650PESTO	l (1		
	7.	01/28/1997	5,597,915	Chambers,	et tet _ eu/		6			
	8.	07/07/1998	5,776,946	McGeer, et	al. RADEMARK OFF		22			
	9.	01/19/1999	5,861,380	Gyorkos, et	- wii	7	E	<u> </u>		
	10.	12/21/1999	6,004,942	Firestein, e	t al.					
	11.	06/27/2000	6,080,588	Glick						
		21810 m 2 m 1888		REIGNIPATIE	NT/DOCUMENTS: 45 4 16	we down		\$6.75 7 1.85		
Examiner	Ref.	Date	Document No.	Name		Class	Subclass	Transla	tion	
Initials	No.							YES	NO	
	12.	06/04/2000	WO 00/19200	PCT					<u> </u>	
				OTHERDO						
Examiner	Ref.	Title	Contains (menoine)	aumorauue, o	ate pertinent pages (etc.)		alatie is			
Initials	No.	11.00						,		
11	13.	Adachi, M., et al., "Aberrant Transcription Caused by the Insertion of an Early Transposable Element in an Intron of the								
V		Fas Antigen Gene of <i>lpr</i> Mice," <i>Proc. Natl. Acad. Sci. USA</i> – <u>90</u> :1756-1760 (1993) —								
- [14.	Adelman, N. 158:1350-13	E., et al., "Treatment o	of (NZB X NZW	F ₁ Disease with Anti-I-A Mo	onoclonal Ai	ntibodies," J	Exp. Med		
	15.			utotovicity of /	Ascorbic Acid and Dehydro	accorbia Ac	id in Novemb	actoma (CV	N CUN	
		and Neuroed	todermal (SK-N-LO) C	ells." <i>Antican</i>	<u>cer Research – 14:221-228 (</u>	(1994)	iu in Neurobi	astoma (SV-	N-3H)	
1	16.	Beale, P.J.,	et al., "BCL-2 Family P	rotein Express	sion and Platinum Drug Res	sistance in O	varian Carci	noma." Britis	zh	
		Journal of C	ancer - 82(2):436-440	(2000)					•••	
	17.	Boojamra, C	.G., et al., "Solid-Phas	e Synthesis of	1,4-Benzodiazepine-2,5-Di Chem. – <u>62</u> :1240-1256 (199	ones. Libra	ry Preparatio	n and		
	18.				thod for the Solid-Phase Sy		A-Renzodiaz	onino Doriva	thron "	
		J. Am. Chem	. Soc <u>114</u> :10997-10	998 (1992)	7-2-0v oona-1 11400 oy	USIS VI I	, viievuidi	~hina nai144	u 7 65,	
	19.	Bunin, B.A.,		orial Synthesis	and Chemical and Biological (1994)	cal Evaluation	on of a 1,4-Be	nzodiazepin	е	
	20.	Chumakov, (1993)	A.M., et al., "Analysis	of p53 Transac	tivation Through High-Affi	nity Binding	Sites," Onco	gene <u>- 8</u> :300	5-3011	
	21.		et al., "Lor and old: S	ingle Gene Mr	odels of Systemic Autoimm	unity and Ly	mphoprolifo	rative Disease	20 11	
			mmunol. – <u>9</u> :243-269 (emy and Ly	hiiohioine	14410 DISTA	, ,	
V	22.	Crabtree, R.	H., "A New Type of Hy	drogen Bond,"	Science - <u>282</u> :2000-2001 (1998) 🗸				
$-\mathcal{M}$	23.	Desoize, B.,	"Anticancer Drug Res	istance and In	hibition of Apoptosis," Ani	cancer Rese	arch - <u>14</u> :22	91-2294 (199	4)	
A	l	1								
EXAMINE	R:		1		DATE CONSIDERED	:	2 1 2 1			
		I citation cash	land whether	ha alé-41				6		
not conside	red. Incl	lude a copy of t	iered, whether or not t his form with next con	πe citation con nmunication to	forms with MPEP 609. Draw	w a line thro	igh the citati	on if not in co	onforma	
154157.1										
193696v1										
. 000001										

		Form PTO-1449	Attorney's Docket No. 128019-203801	Application Serial No. 1020790,101		
			Applicant(s)			
INFO	RMATIO	N DISCLOSURE STATEMENT	Gary D. GLI	J UR Z		
			Filing Date: November 8, 2000	Group Art (Unassigned :		
-	use sev	eral sheets if necessary)		(e)		
		OTHER	DOGUMENIES (Confinution): *** ***			
31	1000	. การที่เกาะเกาะเกาะเกาะเกาะเกาะเกาะเกาะเกาะเกาะ	hor utle date pertinent pages etc.			
11	24.	Doble, A., et al., "Labelling of Periphe	ral-Type Benzodiazepine Binding Sites in Hu	Iman Brain with [3H]PK 11195:		
Anatomical and Subcellular Distribution			on," Brain Research Bulltetin - 18:49-61 (19)	erican Journal of Kidney Diseases -		
	25.	Donadio, J.V., et al., "Immunosuppres 21(3):239-250 (1993)	sive Drug Therapy in Lupus Nephritis," Am	Sea C		
	26.	Frmak TH et al "Treatment of Muri	ne Lupus with Monoclonal Antibody to L3T4	1," Laboratory Investigation		
	20.	61/4\-447-456 (1989) -		دن کا		
	27.	Gallant J.E. et al. "Incidence and Nat	tural History of Cytomegalovirus Disease in	Patients with Advanced Human		
		Immunodeficiency Virus Disease Trea	ated with Zidovudine," The Journal of Infecti	ous Diseases -256:12231227 (1992) /		
	28.	Garcia-Calvo, M., et al. "Inhibition of I	Human Caspases by Peptide-Based and Mac	cromolecular innightors," The Journal		
	20	of Biological Chemistry - 273(49):326	A Strand Breaks Associated with Apoptosis	During Treatment of Leukemias."		
	29.	Leukemia - 7(5):659-670 (1993)	A Straing Dieaks Associated with Apolitonia			
	30.	Gordon, C., et al., "Chronic Therapy v	with Recombinant Tumor Necrosis Factor- $lpha$	in Autoimmune NZB/NZW F ₁ Mice,"		
	00.	Clinical Immunology and Immunopat	hology – 52:421-434 (1989)			
	31.	Gordon, E.M., et al., "Applications of	Combinatorial Technologies to Drug Discov	ery. 2. Combinatorial Organic		
			ies, and Future Directions," Journal of Medic	cinal Chemistry – <u>37(</u> 10):1385-1401		
(1994)						
	32.	Hann, B.H., et al., "Influence of Cyclo	is and Rheumatism – 18(2):145-152 (1975) <i>\(\circ\)</i>	/ Drugs on miniatio bisordoro and		
	33.	Hang 1 et al "A Spontaneous Rhei	umatoid Arthritis-Like Disease in MRL/1 Mic	e," <i>J. Exp. Med.</i> - <u>155</u> :1690-1701 (1982)		
	34.	Horowitz, R.E., et al., "Cyclophospha	mide Treatment of Mouse Systemic Lupus E	rythematosus," <i>Laboratory</i>		
		Investigation - 21(3):199-206 (1969) -				
	35.	Cell - 66:233-243 (1991)	oded by the cDNA for Human Cell Surface Ar			
	36.	Koopman, W.J., et al., "The MRL-lpr/l	pr Mouse. A Model for the Study of Rheuma 988)			
	37.	Korsmeyer, S.J., "Bcl-2 Initiates a Ne	w Category of Oncogenes: Regulators of C			
1	38.	Liu, J.R., et al., "Bci-xL is Expressed	in Ovarian Carcinoma and Modulates Chemo	otherapy-Induced Apoptosis,"		
		Gynecologic Oncology - 70:398-403	(1998) <i>ノ</i>			
	39.	Los, M., et al., "The Role of Caspase	s in Development, Immunity, and Apoptotic	Signal Transduction: Lessons from		
	10	Knockout Mice," Immunity – 10:629-	dition, pp. 436-446 (1978) – Eds. John Wiley	& Sons New York		
	40.	Marino M et al "Prevention of Sys	temic Lupus Erythematosus in MRL/ <i>lpr</i> Mice	by Administration of an		
1 1	-	Immunoglobulin-Binding peptide." A	<i>lature Biotechnology</i> – <u>18</u> :735-739 (2000) 🖊			
	42.	McDonnell, T.J., et al., "Progession f	rom Lymphoid Hyperplasia to High-Grade M	lalignant Lymphoma in Mice		
		Transgenic for the t(14;18)," Nature -	- <u>349:254-256 (1991)</u>	Associated value Esp December A		
	43.	Nagata, S., "Human Autoimmune Ly Lesson from the Mouse Model," J. H	mphoproliferative Syndrome, a Defect in the	Apoptosis-inducing Pas Receptor: A		
 	44.	Churama H et al "Analysis of Def	ective Delayed-Type Hypersensitivity in Aut	oimmune Mice Bearing Ipr Gene," Clin.		
	/ •••	Exp. Immunol 63:87-94 (1986) /				
7	45.	Okuvama, H., et al., "Effect of Cyclo	phosphamide Pretreatment on Defective Del Arch. Allergy Appl. immunol. – <u>88</u> :394-401 (1	ayed-Type Hypersensitivity in 1989) /		
EVA STORY	(DATE CONSIDERED:			
EXAMIN				7 30/06		
EXAMINER not consid	t: initial i ered. Inc	f citation considered, whether or not the clude a copy of this form with next comm	e citation conforms with MPEP 609. Draw a li nunication to applicant.	ne through the citation if not in conforma		
154157.1						
193696v1						

				Form PTO-1449	Attorney's Docket No. 128019-203801 Application Serial No. 09/700,10					
_ [NEC	DMATI	ON DISCLOSURE STATEMENT	Applicant(s)					
ŀ		-		ON DISCLOSURE STATEMENT	Gary D. GLICK, et al.					
			(use se	overal sheets if necessary)	Filing Date: November 8, 2000 Group Art Unit: Unassigned					
Į				OTHER	DOCUMENTS (Continuation)					
ŀ			40	(including aut	Projection Extends (Continuation)					
	-01		40.	2):84-89 (1999) V						
			47.	of a Panel of Human Ovarian Cancer C	of the P53 Status, BCL-2 Expression and Radiation and Platinum Drug Sensitivi Cell Lines," Int. J. Cancer – 77:913-918 (1998)					
1			48.	Levels," Br. J. Cancer - 74(3):380-386	abolism of the Orally Active Platinum Drug JM216: Influence of Glutathione (1996)					
			49.	<u> Nati. Acad. Sci. USA - 90</u> :4409-4413 (1	Autoimmune Ipr/lpr Mice have a Defect in Antigen-Stimulated Suicide," Proc. 1993)					
			50.	Sakata, K., et al., "Role of Fas/Fasl. Inl Immunology and Immunopathology -	teraction in Physiology and Pathology: The Good and the Bad," Clinical 87(1):1-7 (1998)					
	1P	-	51.	Sandstrom, P.A., et al., "Autocrine Pro	oduction of Extracellular Catalase Prevents Apoptosis of the Human CEM T-Cell atl. Acad. Sci. USA – 90:4708-4712 (1993)					
7	5		52.	Schoemaker, H., et al., "Specific High- Pharmacology and Experimental There	Affinity Binding Sites for PHIRo5-4864 in Rat Brain and Kidney." The Journal of					
اً	8 D MA	500	53.	Schwab, M., et al., "Amplified DNA with	th Limited Homology to myc Cellular Oncogene is Shared by Human					
(A	E TRAI	EMP		Neuroblastoma Cell Lines and a Neuroblastoma Tumour," Nature – 305:245-248 (1983) Scott, C.F., et al., "Comparison of Antigen-Specific T Cell Responses in Autoimmune MRL/mp-lpr/lpr and MRL/Mp-+/+ Mice," The Journal of Immunology – 132(2):633-639 (1984)						
Ī	TO AL	ultiple Forms of Apoptosis but not Negative Selection in Thymocytes," Cell -								
			56.	67:879-888 (1991) Sheppard, R.C., et al., "Acid-Labile Res Protein Res. – 20:451-454 (1982)	sin Linkage Agents for Use in Solid Phase Peptide Synthesis," Int. J. Peptide					
			57.	Stevens, S.Y., et al., "Non Nucleic Acid Chemistry," J. Am. Chem. Soc. – 118:	Inhibitors of Protein-DNA Interactions Identified Through Combinatorial					
Ī			58.	Sugimoto, T., et al., "Determination of	Cell Surface Membrane Antigens Common to Both Human Neuroblastoma and					
T		T	59.	Swanson, P.C., et al., "High Resolution	Panel of 38 Monoclonal Antibodies," JNCI – 73(1):51-57 (1984) n Epitope Mapping of an Anti-DNA Autoantibody Using Model DNA Ligands," J. nition by Murine Anti-DNA Autoantibodies," J. Clin. Invest. – 97(7):1748-1760 nphoproliferative Disease in Mice, Caused by a Point Mutation in the Fas Ligand,"					
r		\dagger	60.	Immunology - 152(5):2601-2612 (1994) Swanson, P.C., et al., "Ligand Recogni (1996)						
	-	П	61.	Takahashi, T., et al., "Generalized Lym						
上	-	П	62.	Cell -76:969-976 (1994) Theofilopoulous, A.N., et al., "Murine N	Models of Systemic Lupus Erythematosus," <i>Advances in Immunology</i> – <u>37</u> :269-					
-		\vdash	63.	Thompson, C.B. "Apontosis in the Pat	thogenesis and Treatment of Disease," Science – 267:1456-1462 (1995)					
			64.	Watanabe-Fukunaga. R., et al., "Lymph	hoproliferation Disorder in Mice Explained by Defects in Fas Antigen that					
L				Mediates Apoptosis," Nature - 356:314	4-317 (1992)					
L			65.	White, E., "Life, Death, and the Pursuit	of Apoptosis," Genes & Development - 10:1-15 (1996)					
			66. Wu, G.Y., et al., "Receptor-Mediated in Vitro Gené Transformation by a Soluble DNA Carrier System," The Journal of Biological Chemistry – 262(10):4429-4432 (1987)							
ŀ		\vdash	67.	Wyllie, A.H., "The Genetic Regulation of	of Apoptosis," Current Opinion in Genetics & Development - 5:97-104 (1995)					
┝	- { }	느	68.	<u> Zamzami, N., et al., "Mitochondrial Con</u>	ntrol of Nuclear Apoptosis." J. Exp. Med. – 183:1533-1544 (1996)					
┢	V	1	69.	20ratti, M., et al., "The Mitochondrial Pe	ermeability Transition," Biochimica et Biophysica Acta – 1241:139-176 (1995)					
L	EXAMI				DATE CONSIDERED: 3 70 01					
	±XAMIN 10t cons	ER: side:	Initial if red. Inci	citation considered, whether or not the ci ude a copy of this form with next commur	itation conforms with MPEP 609. Draw a line through the citation if not in conformication to applicant.					
1	54157.1									
1	193696v1									